Pfizer and Moderna Bivalent COVID-19 Vaccines Authorized to Use as Booster Doses in Children Ages Five Years and Older
In an October 12, 2022, announcement, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUA) for the use of Bivalent COVID-19 vaccines from Pfizer BioN-Tech for ages five years and older, and Moderna for ages six years and older, as a booster dose. The American Medical Association (AMA) issued a press release that includes updated Current Procedural Terminology (CPT) codes as shown in the table below.
The Office of MaineCare Services (OMS) will be updating our system to include these codes. We are asking providers to hold all claims for the Pfizer BioN-Tech Bivalent COVID-19 vaccine booster doses and their administration for all members ages five years through 11 years, and for the Moderna Bivalent COVID-19 vaccine booster doses and their administration for all members ages six years through 18 years, until this system update is complete.
|
Moderna COVID-19 Vaccine Bivalent Booster-12 years and older |
|||
|
Code |
Description |
Effective Date |
MaineCare Rate |
|
91313+ |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use |
10/12/22 |
$0* |
|
0134A+ |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose |
10/12/22 |
TBD** |
|
Moderna COVID-19 Vaccine Bivalent Booster-6 to 11 years old |
|||
|
91314 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use |
10/12/22 |
$0* |
|
0144A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose |
10/12/22 |
TBD** |
|
Pfizer BioN-Tech COVID-19 Vaccine Bivalent Booster- 5 to 11 years old |
|||
|
Code |
Description |
Effective Date |
MaineCare Rate |
|
91315 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
10/12/22 |
$0* |
|
0154A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose |
10/12/22 |
TBD** |
|
*Government Supplied Vaccines **Rates for these codes are not yet established +Code previously released 08/31/22 for 18 years and older Note: The COVID-19 vaccine administration codes will be added for roster billing |
|||
This authorization replaces the prior EUAs for the Monovalent COVID-19 vaccine booster dose from Pfizer BioN-Tech for individuals ages five years and older.
|
No Longer Authorized-Pfizer BioN-Tech COVID-19 Vaccine Booster-5 to 11 years old |
|||
|
Code |
Description |
Effective Date |
End Date |
|
91307 |
Pfizer-BioNTech- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
10/29/21 |
10/12/22* |
|
0074A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose |
05/17/22 |
10//12/22 |
|
*Drug is only authorized for use with a Primary Dose Covid Vaccine Series. Do not use this drug code when billing booster doses for the age ranges specified. |
|||
Providers may visit the Maine CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccines and booster doses. The Maine CDC also issued this notice that includes information on COVID-19 vaccine booster doses.
If you have questions about the use of Monovalent or Bivalent COVID-19 vaccine booster doses, please contact your Provider Relations Specialist.
Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.
